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Concern over the inappropriate exclusion of older people from clinical trials 
is longstanding. The PREDICT study used mixed methods to investigate the 
extent of this exclusion and to explore the views of those directly involved. 
This paper reports findings from that aspect of the study investigating the 
views of older people and carers. Drawing on findings from earlier stages 
in the study, a structured interview schedule was developed to form the 
basis of focus group discussions. Groups were held across nine countries: 
the Czech Republic, Israel, Italy, Lithuania, Holland, Poland, Romania, 
Spain and the UK (n = 42). Discussants were those living with conditions 
commonly affecting older people: hypertension, cancer, dementia, heart 
failure, stroke and depression (n = 285). Data were analyzed for differences 
and commonalities within and between groups. Issues raised fell into four 
themes: ageism, both within society and amongst clinicians and researchers; 
advantages and disadvantages to participation; the relationship between 
the participant and their clinician/research team; and practical features to 
support participation. Findings confirm that older people and carers see 
chronological age as an insufficient reason for exclusion from trials and view 
such exclusion as age discrimination. They point to the complex relationship 
between healthcare professionals and trial participants and identify the 
need for cultural and generational sensitivity in trial design, as well as the 
importance of considering adaptations to meet special needs. Finally, they 
identify the need for quality of life to be included as an outcome measure in 
such research and emphasize the importance of including lay perspectives in 
health research design generally.
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There has long been concern over the inappropriate exclusion of older people from 
clinical trials in general and the implications for appropriate prescribing of drugs 
and other treatments. In this paper we present findings from the PREDICT study, 
exploring the views of older people and carers on such exclusion. The paper begins 
with a brief exploration of the background evidence on the inappropriate exclusion of 
older people from clinical trials.  It then turns to the PREDICT study and describes 
the methods employed and outlines findings from the focus groups with older people 
and carers. Finally, the paper concludes with a discussion of the implications of these 
findings for both healthcare and research practice as well as for policy. 
Background
Despite the importance of clinical trials in identifying safe and effective therapeu-
tic interventions, there has been widespread evidence over many years that older 
people have been, and remain, inappropriately excluded from them, with treatment 
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recommendations being extrapolated from results of 
research involving younger populations [1–8]. The 
situation extends across the range of conditions most 
commonly affecting older people, including cancer [9], 
Parkinson’s disease [10], sepsis [11] and heart failure [12]. 
Such exclusion leaves professionals with a difficult deci-
sion: either they do not prescribe because of the lack of 
age-appropriate data or they prescribe despite its lack [4]. 
Either way, it makes safe, effective prescribing of inter-
ventions for older people problematic to say the least, 
with consequent health and financial cost implications 
for both the individual and the community [13]. This 
situation is further complicated by the fact that older 
people often experience more than one condition at the 
same time and therefore may be prescribed a number of 
drugs or treatments simultaneously [13,14]. It is not sur-
prising then, that inappropriate prescribing (IP), which 
is preventable, has been highlighted as a common and 
serious global healthcare problem amongst older peo-
ple, leading to increased risk of adverse drug reactions 
(ADRs); with polypharmacy being the main risk factor 
for both IP and ADRs [15]. Against this background of 
obvious individual patient and societal cost–benefit, the 
persistent exclusion of older people from clinical trials is 
perplexing. It becomes yet more so in the face of increas-
ing awareness of the dramatic ageing of our populations: 
in the last 30 years the number of people in the world 
aged 60 years or older – the United Nation’s definition 
of an older person [16] – has doubled from 378 million 
in 1980 to 759 million in 2010. It is projected to more 
than double again in the next 40 years, rising to two 
billion by 2050, when older people will outnumber chil-
dren – those 14 years and younger – for the first time 
in human history [101]. There are currently 164 million 
older people in Europe and life expectancy is increas-
ing across all European countries [17]. Alongside this 
dramatic shift in demography, we know that the burden 
of disease is higher in older populations and, since they 
outnumber men, higher again amongst older women.
Purpose of the study
In the face of the concerns outlined above, the PREDICT 
study was established to investigate the extent of this 
exclusion and to explore the views of those directly 
involved. The study used a mixed methods approach 
[18–20] to investigate the issue across nine EU partner 
countries: the Czech Republic, Israel, Italy, Lithuania, 
Holland, Poland, Romania, Spain and the UK. Funded 
under the EU’s 7th Framework, the research program 
was organized into a series of work packages (WPs), 
sequentially drawing on preceding methods and findings 
[19]: WP1.1 provided the initial work involving a system-
atic review of the literature on the representation of older 
people in clinical trials [21], with a subsection, WP1.2, 
specifically examining exclusion in ongoing clinical tri-
als in heart failure [12]; WP2 then undertook a survey of 
the opinions of healthcare professionals [22]. Building on 
the findings from WPs1, 1.1 and 2, the research ques-
tions in WP3 were designed to understand older people’s, 
and their informal carers’ views on whether or not they 
should be included in clinical trials. More specifically, 
they sought to explore whether there were particular 
conditions under which they should or should not be 
invited to participate, whether there were any identifiable 
barriers or facilitators to such participation and whether 
people felt that any additional guidelines or legislation 
were necessary to support appropriate inclusion. 
Design & methods
A qualitative approach was adopted, employing a struc-
tured focus group method. This method allows for the 
exploration of a tightly defined topic by individ uals 
involved in a particular situation and is suitable for 
topics that are not considered sensitive or deeply per-
sonal. It also allows for the co-construction of meaning, 
encouraging exploration and debate within the group 
and is particularly suited to accessing lay knowledge [23].
 ■ Participants
Discussants were drawn from those groups living with 
some of the conditions most commonly affecting older 
people, as well as informal carers. It should be noted 
that, as was to be expected, participants often had co-
morbidity. Ages, including those of carers, ranged from 
60 to 87 years and a total of 42 focus groups were held. 
Table 1 indicates the focus groups that were reported 
on by partners.
 ■ Recruitment
Recruitment took place through exist ing patient gro u p s 
in hosp ital settings and via community organ i za tions 
Table 1. Type and number of focus groups 
conducted.
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working with older people. Only those considered able 
to give consent were invited to take part. Standardized 
information letters and consent forms were designed 
and were sent in advance to individuals as part of the 
invitation to participate. Groups consisted of between 
four and 12 participants, of whom 95 were men and 190 
women (n = 285; Figure 1). This ratio was not designed 
but its emergence comes as no surprise since it reflects 
the gender-split amongst older populations throughout 
Europe [24]. 
 ■ Method
The interview schedule for the focus groups was struc-
tured around the research questions outlined earlier, 
which, as mentioned, had been identified through the 
findings from WP1, 1.1 and 2 [18,19]. To assist in stan-
dardization across the partners, a video and protocol 
were produced detailing how to organize and run a 
focus group [102]. 
The groups, which took place in the native language 
of each partner country, had two facilitators. Discussions 
lasted approximately an hour and began with the writ-
ten information on the study being explained orally. 
Discussants were invited to sign the consent forms, if 
they had not already done so, and consent was again 
checked at the end of the discussion. To maintain anon-
ymity, discussants were allocated an alphabetic letter 
that replaced all names within the transcripts and iden-
tifying information was stored separately to transcripts. 
The study was approved by local research ethics com-
mittees or equivalents in the Czech Republic, Israel, 
Poland, Spain, Italy and the UK. National regulations 
and ethical guidelines determined that research ethics 
or institutional review was not required in Lithuania, 
Holland and Romania. A lay summary outlining 
findings was sent to discussants on completion of the 
project.
A pilot focus group was held in each country to vali-
date the interview schedule (n = 9). It was clear that 
the majority of people did not understand the notion 
of a clinical trial and some time was spent in explain-
ing the term before the pilot discussions could begin. 
A standardized lay explanation was therefore devel-
oped for inclusion as part of the information letter 
and the introductory section of the interview schedule. 
Piloting resulted in no other changes and so those group 
discussions have been included in the ana lysis. 
 ■ Analysis
All focus groups were audio recorded and transcribed. 
Analysis took place at a number of discrete levels: a 
researcher from each partner country analyzed their 
data with a specific focus on the research questions 
as outlined in the interview schedule [23]. A search 
was then performed for confirmatory or challenging 
evidence across and within all data sets. In keeping 
with the nature of qualitative and exploratory research, 
the intention was to develop insights that would hold 
theoretical representativeness, rather than being based 
on statistical similarity, that is to say, findings that 
would be sufficiently general as to hold in other con-
texts similar to the one under investigation [25]. Once 
complete, a summary of findings was sent to the lead 
partner (Keele University, UK) for inclusion in the 
final ana lysis. The UK transcripts were used as the 
starting point for this overarching ana lysis. As codes 
emerged from these data, the data from other part-
ners were then checked for additional confirmatory 
or challenging evidence within and between groups, 
and between countries in line with basic principles of 
qualitative data ana lysis [26].
Results
The emergent findings fell into four themes: ageism in 
society generally and amongst clinicians and researchers 
specifically, awareness of advantages and disadvantages 
to participation, the relationship between the partici-
pant and their clinician/research and practical features 
to support participation. More than one quote is used 
where slightly different dimensions to an issue emerged 
and the quotations chosen are those that best illustrate 
and summarize common responses.
 ■ Ageism
Ageism emerged as an overarching theme throughout 
the discussions and exclusion was seen as linked to the 
ways in which older people are valued and respected 
















































Figure 1. Breakdown of gender for focus groups conducted in all partner 
countries.
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• “After a certain age, adult and young people start to 
neglect or leave us aside” (Depression Group, Italy);
• “And let there be a general principle that old man is 
still a man” (Cancer Group, Poland).
The majority of discussants felt exclusion was ageist 
and an infringement of rights: 
• “One thing I would say … they’re discriminating 
against older people in clinical trials and that, where 
it’s appropriate, they should be included” (Dementia 
Carers Group, UK);
• “Medical research is for everybody. There is no diff-
erence between a young adult and a centenarian; they 
are both persons with same rights” (Stroke Group, 
Italy).
Unsurprisingly then, age per se was generally not seen 
as a barrier:
• “I think that the people that take part in the clinical 
trial should be those for which it is thought that the 
medicine will be useful … Age should never be a 
factor in itself” (Dementia Carers Group, Spain);
• “But there are 90 year-olds that could easily get 
involved with a trial. I know a lady of 99 and I 
wouldn’t argue with her because she’d win over me 
any time!” (Dementia Carers Group, UK). 
Yet, for others in the same group age clearly was, if not 
a barrier, at least sufficient reason to decline, highlight-
ing the need for choice on whether or not to participate:
• “My mum and dad wouldn’t … they’re in their nineties, 
so I agree with them to be honest. They’re in their nine-
ties, leave them alone” (Dementia Carers Group, UK).
Discussants were very aware of the shift in demo-
graphy and the importance of taking this into account 
in generating good science. Indeed, the fact that older 
people can be excluded from trials produced a surprised 
response:
• “But these medications are meant for old people, they 
can’t test them on 20-year olds!” (Pilot Group, 
Poland).
However, an underlying sense of ageism amongst 
discussants themselves was also evident:
• “It is not so important for us – it is more important 
to attempt for the grandchildren, for the future 
generations” (Hypertension Group, Lithuania);
• “There is no point in investing research money in old 
people; it is preferable to invest in younger people” 
(Depression Group, Israel).
Or yet more starkly:
• “Elderly people soon die; therefore you cannot make 
a big harm” (Diabetes Group, Czech Republic).
Discussants appeared very aware that the ageing proc-
ess affects how an individual will respond to different 
drugs or therapies and that diversity amongst the older 
population needs to be taken into account in sampling: 
• “A body at 40-years old reacts in a certain way to a 
drug, at 60-years old the body has another reaction 
and at 80-years old or above, another one” (Pilot 
Group, Romania).
Discussants generally perceived increased morbidity 
and polypharmacy as a clear reason for inclusion:
• “As we get older, we are prescribed more and more 
drugs … I mean, I have so many I rattle! It’s awful, 
you know, and I just wonder whether there’s enough 
research gone into what we are given and why, and 
the effects of the combinations…” (Stroke Group, 
UK);
• “Older persons use the majority of drugs. It is a para-
dox that persons who usually take more medicines are 
excluded from clinical trials investigating such 
medicines” (Cancer Group, Italy).
 ■ Advantages & disadvantages to participation
Participation was not seen as without risk and caution 
was deemed necessary in cases of frailty where the health 
of the individual was so poor, such that any additional 
burden might have negative effect:
• “Well, being older and having more diseases and 
entering a trial with a drug, you cannot be sure on 
the body’s reactions. Take, for example, the heart, 
now you can be ok and the next second you close your 
eyes. Your blood pressure may increase, or you may 
have a stroke” (Pilot Group, Romania).
Linked to this was concern that participating in 
research such as trials might disrupt existing, effective 
coping and management strategies, and also that out-
come measures focused simply on extending life years 
were insufficient reason to take part: 
• “I would not participate in a clinical trial and I 
wouldn’t allow that a relative of mine would be given 
medicine, if it’s only to prolong life…” (Dementia 
Carers Group, Spain);
• “I mean, it is improving this part of life … It’s the 
possibility of improving that, you know, so that peo-
ple can make the most of that additional life that is 
coming really, which is important” (Carers Group, 
UK).
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Nonetheless, risk was also seen as unavoidable:
• “I think that without risk nothing can be done in this 
matter” (Dementia Group, Poland).
Motivating factors to becoming involved fell into two 
categories; benefits to others and to oneself, of which 
the former appeared dominant: 
• “In the short run the profit is not mine personally, in 
the long run the profit is to the general population” 
(Pilot Group, Israel);
• “Because it’s a beautiful thing if you can help others 
in their grave diseases” (Cancer Group, Poland). 
For others, participating in clinical trials could offer 
a degree of hope for oneself, including possible improve-
ments in quality of life:
•  “I hope that this thing may eventually help me” 
(Cancer Group, Poland);
• “Researchers can help us to have a good life in spite of 
the diseases we are affected from” (Stroke Group, Italy).
 ■ Consent & relationship with 
clinician/research team
First amongst those processes that could mitigate risks to 
participation was the reliability of the person suggesting 
inclusion, almost invariably seen ideally as a physician:
• “It must be said by a physician I visit regularly … Then 
I would like to agree, because my physician tells me 
this” (Depression Group, Poland);
• “I believe the doctor. He simply wants what is good 
for me” (Pilot Group, Israel).
This relationship between the potential participant 
and the person issuing the invitation to take part was 
seen as so crucial that being approached cold was not 
considered generally acceptable:
• “I was sent some literature, I think it was probably 
just one of these ‘drops’, about whether I’d like to take 
part in bowel cancer trials, would I send samples and 
I declined the offer because … it didn’t come from a 
doctor’s referral” (Pilot Group, UK).
For the vast majority the relationship extended to 
management of the clinical trial itself: 
• “[The person] who carries out the clinical trial should 
be a physician so that I can have confidence in him” 
(Heart Failure Group, Poland);
•  “Through direct communication with the physician 
who follows you in this trial you feel protected” (Pilot 
Group, Romania).
This emphasis on the role of the physician was tied to 
issues of safety and the importance of close scrutiny in 
both monitoring trials generally and the overall health 
of individual participants: 
• “I am for testing drugs but it must be under the 
highest clinical control” (Cancer Group, Poland);
• “Public institutions and universities should lead med-
ical research, then private drug companies can be 
involved but they should remain under supervision” 
(Carers Group, Italy).
Discussants were very aware that the final decision 
on whether or not to take part must remain with the 
individual, or if that was not possible, with their family: 
•  “Only in such a situation it is the family who must 
decide whether to include an infirm person, one that 
is unaware, in clinical tests … no medication must 
be given without consent” (Pilot Group, Poland).
Crucial to consent was clear information: 
• “As for the question you asked me, whether I would 
agree to take part in a clinical trial, I think I would, 
as long as there was information behind it” (Dementia 
Carers Group, Spain).
It was felt that information was not always available 
in an accessible form: 
• “But generally those leaflets are written in a very 
sophisticated, specialist language … and when a 
patient finished two grades of a primary school will 
he understand a lot of that?” (Pilot Group, Poland).
The importance of ongoing explanations was also 
emphasized:
• “Doctors are not explaining, every time” (Cancer 
Group, Lithuania);
• “You take part in it, but you don’t even know how 
this investigation is developing. You don’t know if it’s 
going somewhere or not” (Cerebrovascular Carers 
Group, Spain).
The discussion on information also included refer-
ences to the lack of feedback some felt they received 
about the outcomes of research they did take part in, 
as one of the few people to have experience of a clinical 
trial pointed out:
• “I really would like to know the results of clinical 
trials in which my relatives were involved, but nobody 
told me anything” (Carers Group, Italy).
At a broader information level, greater public aware-
ness of the importance of trials was advocated as a way 
of increasing participation: 
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• “If older persons become more aware of the problem, 
they will get involved more easily” (Depression 
Group, Italy).
 ■ Practical aspects to participation
Discussants also identified some practical issues in being 
able to participate:
• “Well, I cannot go because I am very old. If I had 
someone to bring me and take me from there, I can 
go, for sure” (Pilot Group, Romania). 
People were aware that such support would come 
frequently from families and carers and where they felt 
that taking part might put additional pressure on carers, 
they expressed a reluctance to participate. This concern 
was rooted in reality, as the experience of this Italian 
carer indicates: 
• “The participation was really hard work. I had to give 
one more pill every day – he was already taking several 
pills – and write notes on them every day. It lasted 
1.5 years and every 3 months I had to bring him to 
the follow-up visit. Each visit was really extensive, 
lasted long and included an ECG” (Carers Group, 
Italy).
These difficulties could be further heightened when 
carers themselves were in poor health:
• “My only problem as a carer is that I’m the same age and 
I’m a walking stroke in that I’ve got high blood pressure, 
diabetes and cholesterol” (Carers Group, UK). 
The location of the trial was also considered to be an 
important factor in an individual’s capacity to take part, 
as was access to transport. For the majority of people, as 
has been seen, having a trial located in a hospital gave 
an additional sense of security in emphasizing that they 
would be more closely monitored. However, for others 
having to travel to participate was seen as a disadvantage:
• “[The researchers] won’t do the tests at home, so then 
they have to go to the laboratory or hospital. That’s 
why I think this would be a problem” (Pilot Group, 
Spain);
• “Often, older persons have walking difficulties and 
are not able to reach the research centers or the hos-
pitals” (Cancer Group, Italy).
 ■ Legislation & the role of a charter
Greatest diversity in opinion was expressed in responses 
to the question of whether legislation would help in 
supporting participation. Some were positive: 
• “Only that I think it is important that they are regu-
lated and that they have guidelines, because there are 
people, the drug companies, with vested interests, 
aren’t there?” (Carers Group, UK). 
Yet it was also considered to be so evidently sensible, 
and in the interests of good science, to include older 
people, that there ought to be no need for legislation:
• “I don’t think that they have to create a similar law 
so older people can participate” (Dementia Carers 
Group, Spain);
• “What I feel is that the people who are doing the 
research in the first place, why have they got to have 
a government regulation … it seems like ordinary 
brain common sense to include a whole range” 
(Dementia Carers Group, UK).
In addition, there was also feeling that existing regu-
lation should be sufficient:
• “We’re already covered under the Age Discrimination 
Act” (Depression Group, UK).
The development of a charter was seen as a natu-
ral consequence of acknowledging that participation 
was important and was also linked to increasing public 
awareness on the issue:
• “It may be useful to write and disseminate a charter. 
It can help older persons to be aware about clinical 
trials and to be informed about medical research” 
(Stroke Group, Italy).
However, there was some unease about government 
involvement generally as well as a lack of faith in the 
ability of a charter to deliver change, again rooted in 
a heavy emphasis on the relationship with physicians:
• “We have our historical experiences with charters. We 
do not need to do anything like this. We trust our 
doctors, our specialists. They lead us till the end” 
(Pilot Group, Czech Republic).
For some people this distrust of formal frameworks 
was at a more general and stark level:
• “Nobody follows neither regulations, neither moral 
norms” (Cancer Group, Lithuania).
Discussion 
• “I think it is important [to include older people], 
because only then you have the choice whether to 
participate or not. Now you don’t have a choice” 
(Stroke Group, Holland).
In the light of these findings we now examine what 
appear to us to be the key policy, practice and research 
implications. As the context in which the study took 
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place, it is necessary to reflect on the vast cultural diver-
sity within Europe. Such diversity goes deep: Europe in 
the 20th century underwent profound upheaval, eco-
nomically, politically and socially. The nation states that 
make up what is now the EU have emerged from this 
period of immense turmoil with varied experiences, as 
have those individuals who are aged 60 years and over: 
some have experienced extreme and prolonged perse-
cution, whilst others have escaped more lightly; some 
have been able to take advantage of improved employ-
ment and health and social care opportunities, others 
have remained in severe poverty and social exclusion. 
Moreover, such experiences are age-cohort specific, 
with the oldest having greater exposure to the intensity 
of change than the emerging baby-boom generation. 
This diversity is reflected in a recent survey of 28 nation 
states, which reported that the average age at which 
youth is perceived to end varies considerably, from 34 
in Sweden to 52 in Greece [17]. 
Turning to our findings, it was clear that despite the 
diversity highlighted above, there was a general con-
sensus across all themes. First amongst these was age-
ism, which was clearly an overarching theme running 
through all of the discussions. At an individual level, 
discussants spoke powerfully of experiences of such dis-
crimination in their lives and clearly saw exclusion on 
age grounds as an infringement of human rights. It is 
now more than 35 years since Robert Butler’s Pulitzer 
Prize-winning book identified ageism as a prejudice 
leading to older people facing insufficient pensions, 
marginal housing and inadequate medical care [27]. Yet 
discrimination on age grounds still appears rife; in the 
most recent European Social Survey, 44% of 58,988 
respondents reported it as a very serious or quite serious 
problem [17]; and a recent UK review of NHS referrals 
found that a significant number of decisions are based 
solely on the patient’s age, rather than the individual’s 
needs or fitness levels [28]. Such ageism is reflected in the 
work of Bayer and Tadd, who found that in 155 studies 
in the UK relevant to older people, more than half had 
an unjustifiable upper age limit and neither the local 
nor the multicentered research ethics committees had 
challenged this [3]. A more recent review suggests that 
the scale of such discrimination is declining but notes 
that unjustified age limits remain frequent in the proto-
cols of intervention studies [29]. It has also been pointed 
out that many clinicians in the USA and Europe have 
an inherent bias that associates older age with poorer 
outcomes from participation in trials [22,30]. Findings 
here challenge such negative stereotyping in pointing 
out that older people themselves consider neither age 
nor cognitive impairment sufficient reason for exclusion. 
They do, however, emphasize the need for close moni-
toring of trial participants, and that improved quality 
of life – rather than simply extending years – should 
be amongst the main outcome measures. They also 
indicate that where an individual may be unable to 
consent for themselves, those who are next of kin must 
be involved fully in the decision-making process and 
retain ultimate authority. However, there was a degree 
of ageism expressed on the part of discussants them-
selves, which may be due to the ways in which older 
people believe the stereotypes they hear about them-
selves [31], which signals the complexities in addressing 
this issue. In addition, and again contrary to the views 
of many professionals, discussants generally perceived 
increased morbidity and the resulting polypharmacy 
as clear rationale for inclusion, rather than exclusion. 
Indeed, members of the UK Dementia Carers Group 
identified only three areas where older people should 
not be included in clinical trials; conditions focused on 
young people, hormone replacement therapy and birth 
control. Furthermore, with women both outnumbering 
men demographically and consuming more medicines, 
exclusion from clinical trials is a highly sexist issue [4]. 
Second, responsibility and accountability in clinical 
trials was highlighted by discussants as of key impor-
tance and is a major challenge to those commission-
ing and carrying out research in this field. Trials are 
commonly conducted by large drug and medical device 
companies as part of their process of product develop-
ment. However, as was reflected in concerns expressed 
in the focus groups, such companies can have very nega-
tive public opinion ratings and key to the success or 
otherwise of a trial are collaborations with clinicians in 
the field [32]. Such collaboration can lead to powerful 
conflicts of interests in which the human participants 
in trials can be greatly disadvantaged. Although one or 
two discussants voiced disappointment in their relation-
ship with their physician, for the majority of people in 
the study this was clearly a relationship of great trust, 
whether with their family doctor or a hospital-based spe-
cialist [33]. The trust described by discussants is ethically 
challenging, particularly in the light of the reliance of 
patients on the expertise and advice of their physicians 
[34]. A recent study exploring oncologists’ commu-
nication strategies in seeking informed consent from 
patients, identified that they “used persuasive commu-
nication, made explicit recommendations, or implicitly 
expressed a treatment preference and were choice limit-
ing” [35]. Adding to this, misreporting of trial findings, 
and indeed failure to publish at all in some instances, 
resulting in delays in generation of knowledge and in 
certain cases patients suffering and dying unnecessar-
ily, have been identified as significant issues [32]. Even 
when conducted to the highest standards, adverse affects 
can be severe, as the recent example of the first-in-man 
clinical trial of TGN412 (intended to treat rheumatoid 
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arthritis, leukemia and multiple sclerosis) showed, where 
six healthy male volunteers developed multiorgan failure 
and required critical care [36]. 
Closely linked to this notion of accountability, 
concerns were expressed by discussants in relation to 
legislation and developing a charter, and it is in these 
discussions that opinions were most divided, perhaps 
unsurprising given the political history of Europe. One 
might surmise that previous life experiences of state-led 
oppression might leave some people with a profound dis-
trust of legislation of any form, yet equally one might 
suppose that it could generate a more passionate avoca-
tion of such frameworks: we cannot say from this work. 
What is clear is that, whilst formal legislation was not 
on the whole deemed to be appropriate, it seemed that 
people generally felt a charter would be useful, not least 
in raising public awareness of the issue. Indeed, discus-
sants felt that existing laws should be sufficient and that 
it was the lack of their implementation that should be 
addressed. In keeping with this, there can be no doubt 
that the European Convention on Human Rights, first 
drawn up in 1950, has had a substantial impact on laws 
throughout Europe. However, as Peter Townsend points 
out, “justifiable and constitutionally entrenched Acts do 
not provide a complete answer … Public officials, rights 
activists, politicians and individual citizens have to share 
responsibility for acceptance and institutionalization 
of rights” [37]. This highlights the still substantial gap 
between antidiscriminatory legislation and practice, and 
supports the argument that challenging ageism requires 
a fundamental paradigm shift, not just at an individual 
and local level but globally [38]. 
Third, whilst crucial to the ethical integrity of any 
research involving human participants, the importance 
of informed consent in the light of the potential risks 
often associated with clinical trials is further highlighted. 
Therefore, it is worrying to note that the extent to which 
participants do indeed give fully informed consent 
remains seriously contested [34,35,39–43]. Discussants here 
highlighted the crucial importance of clear, access ible 
information as a fundamental prerequisite to consent and 
participation. Such information needs to be in a variety 
of formats that can be easily understood by a diverse sam-
ple, including those with impaired cognitive function [44] 
and it should not be assumed that everyone can read, or 
that they will disclose that fact, or that their grasp of lan-
guage allows understanding of difficult concepts [45]. To 
ensure adequate understanding, additional steps should 
be taken; for example, by discussing the protocol in lay 
terms and in detail, ensuring an environment where any 
hearing difficulties will not be magnified, allowing suf-
ficient time for the individual to process details and ask 
questions and creating an atmosphere where they feel 
empowered to do so [46]. Again, the language of clinical 
trials adds a further imperative to such requirements: 
whilst the term is one that is commonly found in the 
media, it is in fact a highly complex research method [47]. 
It was clear from this study that discussants’ understand-
ings were generally very limited, reflected in the fact that 
only ten people across all nine countries self-identified 
as having experience of trials, either personally or vicari-
ously. Whilst difficulty in understanding could be at the 
level of education, it could also be more linguistically 
complex: the Polish for clinical trials, for example, is 
‘badanie kliniczne’, a term which can be itself mislead-
ing as it is easily confused with an extensive medical 
examination or with being selected to receive therapies 
that are not generally available because of expense. At a 
yet more profound emotional level, some reservations 
were expressed amongst discussants who were Holocaust 
survivors and for whom the term ‘clinical research’ holds 
a highly charged, deeply disturbing connotation. All of 
which again emphasizes the need for information that 
is sensitive, not only educationally but also culturally 
and generationally. 
Finally, the importance of including lay perspectives 
in research planning, development and outcome assess-
ment emerged strongly. Fundamental to this – and an 
important ethical dimension to information giving 
increasingly recognized in work on user involvement 
in public services [48] – is giving meaningful feedback 
to participants about the research in which they have 
been/are involved. Such feedback is key to embodying 
anti-ageism principles and challenging the myths that 
currently constitute the barriers facing the inclusion of 
older people in clinical trial research. It should be an 
ongoing part of the research process itself and not just 
feature – at best – at the conclusion. Another expression 
of anti-ageist principles and valuing lay engagement lies 
in the degree to which research seeks to practically facili-
tate the contribution of older people [49]. In addition to 
practical issues such as disabled access and support for 
those with mobility and/or sight and/or hearing dif-
ficulties, appropriate transport, and clear information 
on what to expect at each visit, such measures include 
account being taken of the needs of carers. This latter is, 
an issue that cannot be over-emphasized, since placing 
additional burdens on carers can affect both recruitment 
and retention, in addition to having potentially adverse 
affects on the carer themselves [45,50]. 
Future perspective
Including older people in the clinical trials of treat-
ments that will be available to them is sound science. 
As the world’s population continues to age the impera-
tive to do so will increase with IP and ADRs carrying 
a proportionate increase in human and financial costs. 
Including older people will require increasing attention 
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to appropriate communication and support strategies, 
spanning a range of issues from the content of informa-
tion and how it is delivered, through to transport and 
support for carers. Developing clinical trials that have 
the resources for such inclusion, will require the advice 
and perspectives of older people themselves. 
 ■ Limitations
Owing to time constraints, it was not possible to have 
all the transcripts translated in full into the language 
of the lead institution (English). This inevitably has 
led to a degree of limitation on the level and detail of 
ana lysis possible, which was restricted to simple content 
ana lysis and was not linked to individual biographies 
or sociodemographic circumstances. Linking in such a 
way and thus providing a life-course context for indi-
vidual views might yield pertinent results since, as was 
pointed out earlier, those individuals who lived through 
the last world war and those who have experienced state 
oppression, forced migration or discrimination during 
their lives may have different views on the meanings 
of community, or on the importance of helping oth-
ers, than those who have experienced a good quality 
of life. Alternatively, they may hold the same views but 
for different reasons: the study has not accessed those 
nuanced differences, nor was it able to fully account 
for differences between age cohorts, gender, ethnicity 
or disability. 
The themes that emerged from the study have been 
incorporated into the European Charter on the Rights 
of Older People in Clinical Trials [103]. 
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